$0.4463
0.045711.41%
Last update: Oct 27, 7:49 PM
Humacyte Inc (HUMA) Stock Price, Quote, News & History
HUMANASDAQ
Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a dilutive $50M share offering.
You can purchase shares of Humacyte (NASDAQ:HUMA) through any online brokerage.
Other companies in Humacyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Humacyte has a consensus price target of $5.11.
The stock price for Humacyte (NASDAQ: HUMA) is $0.4501 last updated October 27, 2026 at 7:49 PM EDT.
There are no upcoming dividends for Humacyte.
Humacyte does not have any upcoming earnings scheduled.
There is no upcoming split for Humacyte.
Humacyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and...
